Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016


  • Products Id :- GMDHC8460IDB
  • |
  • Pages: 172
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016', provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer

- The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects

- The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Human Papillomavirus (HPV) Associated Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Overview 10

Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis 11

Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 12

Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 15

Human Papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Human Papillomavirus (HPV) Associated Cancer - Products under Development by Companies 19

Human Papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 22

Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 23

Admedus Ltd 23

Advaxis, Inc. 24

Antigen Express, Inc. 25

Bionor Pharma ASA 26

BioNTech AG 27

Cancer Research Technology Limited 28

Cell Medica Limited 29

Etubics Corporation 30

EyeGene, Inc. 31

Formune S.L. 32

Genexine, Inc. 33

Genticel S.A. 34

iBio, Inc. 35

Immunovaccine, Inc. 36

Inovio Pharmaceuticals, Inc. 37

Inthera Bioscience AG 38

Johnson & Johnson 39

Karyopharm Therapeutics, Inc. 40

Kite Pharma, Inc. 41

MedImmune, LLC 42

Novartis AG 43

Onconova Therapeutics, Inc. 44

Oryx GmbH & Co. KG 45

Profectus BioSciences, Inc. 46

Selecta Biosciences, Inc. 47

Shantha Biotechnics Limited 48

Sirnaomics, Inc. 49

Theravectys SA 50

THEVAX Genetics Vaccine USA Inc 51

Tomegavax, Inc. 52

Transgene SA 53

UbiVac, LLC 54

Vaccibody AS 55

Vault Pharma Inc. 56

Virometix AG 57

ViroStatics srl 58

VLPbio 59

Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 60

Assessment by Monotherapy Products 60

Assessment by Target 61

Assessment by Mechanism of Action 63

Assessment by Route of Administration 65

Assessment by Molecule Type 67

Drug Profiles 69

ABI-1968 - Drug Profile 69

AEH-10p - Drug Profile 70

alpelisib - Drug Profile 71

Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 74

Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 75

BVAC-C - Drug Profile 76

Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 77

Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 78

Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 80

CerviVax - Drug Profile 82

CMD-004 - Drug Profile 83

DPV-001 - Drug Profile 84

DPXE-7 - Drug Profile 86

EDA-HPVE7 - Drug Profile 87

EG-HPV - Drug Profile 88

Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 89

ETBX-041 - Drug Profile 90

GTL-001 - Drug Profile 91

GTL-002 - Drug Profile 94

GX-188E - Drug Profile 95

human papillomavirus (7-valent) vaccine - Drug Profile 97

human papillomavirus [Serotype 16] vaccine - Drug Profile 98

human papillomavirus [serotypes 16] vaccine - Drug Profile 99

human papillomavirus vaccine - Drug Profile 100

human papillomavirus vaccine - Drug Profile 101

human papillomavirus vaccine - Drug Profile 102

human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 103

INO-3106 - Drug Profile 104

INO-3112 - Drug Profile 105

Lm-LLO-ISG15 - Drug Profile 107

LN-145 - Drug Profile 109

Monoclonal Antibody to Target E6 and E7 Proteins for Oncology - Drug Profile 111

NIT-02 - Drug Profile 112

NP-001 - Drug Profile 113

PVX-01 - Drug Profile 114

Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 115

Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 116

rigosertib sodium - Drug Profile 117

sdCMV-002 - Drug Profile 128

SEL-701 - Drug Profile 129

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 130

Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile 131

STP-909 - Drug Profile 132

Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile 133

Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 134

TA-CIN - Drug Profile 135

TG-4001 - Drug Profile 136

TVGV-1 - Drug Profile 138

Vacc-HPV - Drug Profile 139

Vaccine for HIV and HPV Associated Cancer - Drug Profile 140

Vaccine for HPV Associated Cancer - Drug Profile 141

Vaccine for HPV Associated Cancers - Drug Profile 142

Vaccine for HPV Associated Cervical Cancer - Drug Profile 143

Vaccine for HPV Associated Cervical Cancer - Drug Profile 144

Vaccine for HPV Associated Cervical Cancer - Drug Profile 145

Vaccine for HPV Associated Skin Cancer - Drug Profile 146

Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile 147

VB-1016 - Drug Profile 148

verdinexor - Drug Profile 150

VGX-3100 - Drug Profile 151

Vicoryx - Drug Profile 154

VMT-2 - Drug Profile 155

VPI-241 - Drug Profile 156

Vvax-001 - Drug Profile 157

Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 158

Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 160

Featured News & Press Releases 160

Appendix 167

Methodology 167

Coverage 167

Secondary Research 167

Primary Research 167

Expert Panel Validation 167

Contact Us 167

Disclaimer 168

List of Figures

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016 14

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 64

Number of Products by Top 10 Targets, H2 2016 65

Number of Products by Stage and Top 10 Targets, H2 2016 65

Number of Products by Mechanism of Actions, H2 2016 67

Number of Products by Stage and Mechanism of Actions, H2 2016 67

Number of Products by Top 10 Routes of Administration, H2 2016 69

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 69

Number of Products by Top 10 Molecule Types, H2 2016 71

Number of Products by Stage and Top 10 Molecule Types, H2 2016 71

List of Tables

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016 14

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Investigation by Universities/Institutes, H2 2016 26

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2016 27

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H2 2016 28

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2016 29

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2016 30

Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2016 31

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H2 2016 32

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cell Medica Limited, H2 2016 33

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2016 34

Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2016 35

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2016 36

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2016 37

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genticel S.A., H2 2016 38

Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2016 39

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H2 2016 40

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 41

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inthera Bioscience AG, H2 2016 42

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2016 43

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 44

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H2 2016 45

Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2016 46

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H2 2016 47

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2016 48

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016 49

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H2 2016 50

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences, Inc., H2 2016 51

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H2 2016 52

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2016 53

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H2 2016 54

Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016 55

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Tomegavax, Inc., H2 2016 56

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2016 57

Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac, LLC, H2 2016 58

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2016 59

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc., H2 2016 60

Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H2 2016 61

Human Papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics srl, H2 2016 62

Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H2 2016 63

Assessment by Monotherapy Products, H2 2016 64

Number of Products by Stage and Target, H2 2016 66

Number of Products by Stage and Mechanism of Action, H2 2016 68

Number of Products by Stage and Route of Administration, H2 2016 70

Number of Products by Stage and Molecule Type, H2 2016 72

Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2016 162

Human Papillomavirus (HPV) Associated Cancer - Dormant Projects (Contd..1), H2 2016 163

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Admedus Ltd

Advaxis, Inc.

Antigen Express, Inc.

Bionor Pharma ASA

BioNTech AG

Cancer Research Technology Limited

Cell Medica Limited

Etubics Corporation

EyeGene, Inc.

Formune S.L.

Genexine, Inc.

Genticel S.A.

iBio, Inc.

Immunovaccine, Inc.

Inovio Pharmaceuticals, Inc.

Inthera Bioscience AG

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

MedImmune, LLC

Novartis AG

Onconova Therapeutics, Inc.

Oryx GmbH & Co. KG

Profectus BioSciences, Inc.

Selecta Biosciences, Inc.

Shantha Biotechnics Limited

Sirnaomics, Inc.

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Tomegavax, Inc.

Transgene SA

UbiVac, LLC

Vaccibody AS

Vault Pharma Inc.

Virometix AG

ViroStatics srl

VLPbio

Human papillomavirus (HPV) Associated Cancer Therapeutic Products under Development, Key Players in Human papillomavirus (HPV) Associated Cancer Therapeutics, Human papillomavirus (HPV) Associated Cancer Pipeline Overview, Human papillomavirus (HPV) Associated Cancer Pipeline, Human papillomavirus (HPV) Associated Cancer Pipeline Assessment

select a license

Single User License
USD 2000 INR 128160
Site License
USD 4000 INR 256320
Corporate User License
USD 6000 INR 384480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com